

UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION

February 24, 2020

In The Matter Of	:	
	:	
Eastgate Biotech Corp.	:	ORDER OF SUSPENSION
	:	OF TRADING
File No. 500-1	:	

It appears to the Securities and Exchange Commission that the public interest and the protection of investors require a suspension of trading in the securities of Eastgate Biotech Corp. (“ETBI”) (CIK #0001099574) because of concerns about the adequacy and reliability of publicly available information concerning ETBI, including since at least January 30, 2020, among other things, statements about the company’s purported international marketing rights to an approved coronavirus treatment to potentially combat the Wuhan Coronavirus and disclosures by the Company in their September 30, 2019 Quarterly Report regarding their issued and outstanding shares. ETBI is a Nevada corporation having its principal executive offices in Toronto, Canada, and its common stock is quoted on OTC Link (previously “Pink Sheets”) operated by OTC Markets Group, Inc. under the ticker symbol ETBI. The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed company.

THEREFORE, IT IS ORDERED, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed company is suspended for the period from 9:30 a.m. EST on February 24, 2020 through 11:59 p.m. EST on March 6, 2020.

By the Commission.

Vanessa A. Countryman
Secretary